Home Page

In this free webinar, learn about the challenges associated with the EU IVDR regulation. Attendees will gain insights into solutions to help overcome some IVDR hurdles for global clinical trials. The featured speakers will share key considerations when planning for CDx trials with EU sites. Attendees will learn where to look for key information required for CPS submissions. The speakers will also discuss EU country-specific regulatory intelligence.

TORONTO, March 27, 2024 /PRNewswire-PRWeb/ -- From May 2022 onwards, clinical trial assays being developed as companion diagnostics (CDx) need to meet the requirements of the European Union In Vitro Diagnostics Regulation (EU IVDR; Regulation (EU) 2017/746 (EU IVDR)), which includes more stringent oversight during the clinical performance study (CPS) phase of development.

This raises challenges for global CDx trials that contain EU subject recruitment sites, especially with the delay in the full implementation of the European Database on Medical Devices (EUDAMED) and its clinical investigations and performance studies module.

The clinical investigations and performance studies module is still not functional (as of early 2024); consequently, CPS applications and corresponding ethics committee reviews must be submitted to each competent authority and ethics board, which then necessitates co-ordination across multiple jurisdictions in the EU for trials recruiting across multiple EU countries. This can add significantly to the trial set-up time for interventional and registrational in vitro diagnostics (IVD) trials incorporating EU sites.

In this webinar, the expert speakers will focus on their experience with IVDR and describe strategies for solving the specific challenges faced during the IVDR submission process for clinical trial assays being utilised as CDx, allowing global trials to commence and complete in a timely manner.

Register for this webinar today where experts will share their experience with the EU IVDR and provide insights into solving challenges faced during the EU IVDR submission process.

Join experts from Almac Diagnostic Services, Dr. Stewart McWilliams, Global VP Quality and Regulatory Affairs; and Dr. Edwina Duncan, Global Head of Regulatory Affairs, for the live webinar on Wednesday, April 17, 2024, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Overcoming EU IVDR Challenges When Using Clinical Trial Assays to Accelerate Global CDx Trials.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/

Media Contact

Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, vkovacevic@xtalks.com, https://www.xtalks.com

View original content to download multimedia:https://www.prweb.com/releases/overcoming-eu-ivdr-challenges-when-using-clinical-trial-assays-to-accelerate-global-cdx-trials-upcoming-webinar-hosted-by-xtalks-302100260.html

SOURCE Xtalks